Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Return on Sales (2020 - 2025)

Fulcrum Therapeutics (FULC) has 6 years of Return on Sales data on record, last reported at 0.01% in Q2 2025.

  • On a quarterly basis, Return on Sales fell 2.0% to 0.01% in Q2 2025 year-over-year; TTM through Jun 2025 was 0.01%, a 1.0% decrease, with the full-year FY2024 number at 0.0%, up 35.0% from a year prior.
  • Return on Sales reached 0.01% in Q2 2025 per FULC's latest filing, down from 0.0% in the prior quarter.
  • Over the last five years, Return on Sales for FULC hit a ceiling of 0.01% in Q2 2024 and a floor of 0.84% in Q1 2023.
  • A 5-year average of 0.18% and a median of 0.1% in 2022 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -74bps in 2023, then surged 44bps in 2024.
  • Tracing FULC's Return on Sales over 5 years: stood at 0.05% in 2021, then plummeted by -722bps to 0.38% in 2022, then increased by 26bps to 0.28% in 2023, then soared by 100bps to 0.0% in 2024, then plummeted by -653bps to 0.01% in 2025.
  • Business Quant data shows Return on Sales for FULC at 0.01% in Q2 2025, 0.0% in Q4 2024, and 0.0% in Q3 2024.